Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease

Wang, E. S.; Sun, Ying; Guo, Jianqiang; Gao, Xin; Hu, Jianwei; Zhou, Lei; Jiang, Chengchuan

doi:10.1111/j.1600-0404.2009.01318.x

Cited by 39 publications

(40 citation statements)

References 46 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemistry showed tetranectin immunoreactivity in neurons and dendrites, and a lack of staining in glial cells in the cerebrum and cerebellum, and the source of tetranectin in the CSF is believed to be the central nervous system [28]. Our previous study demonstrated that tetranectin was present at reduced levels in PD patients in comparison to normal controls [29]. In the present study, we further confirmed these results and found that tetranectin levels were significantly elevated after STN DBS.…”

Section: Discussionsupporting

confidence: 80%

Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation

Wang

Yao

Chen

et al. 2013

Cell Physiol Biochem

858

View full text Add to dashboard Cite

Aims: To investigate alterations in protein expression associated with deep brain stimulation (DBS) in an attempt to elucidate possible mechanisms of action. Methods: Cerebrospinal fluid (CSF), obtained from six Parkinson's disease (PD) patients (pre- and post-DBS) and from six normal healthy controls, was studied for differentially expressed proteins. 2-D DIGE, in combination with MALDI-TOF and TOF-TOF Mass Spectrometry (MS) or ESI-MS, was used to identify the changed proteins (3 PD patients and 3 controls). Selected proteins were further studied using western blotting (6 PD patients and 6 controls). Results: Twenty-one proteins were identified after MS and protein database interrogation. Apart from apolipoprotein A-I (apoA-I), the expression levels of complement C4 (C4), IgA, tetranectin, and extracellular superoxide dismutase (EC-SOD), detected by western blotting, correlated well with the 2-D DIGE results. In the follow-up period, the expression levels of C4, apoA-I and IgA were stable whereas EC-SOD and tetranectin were significantly elevated. In addition, when DBS was ceased in one patient due to a suicide attempt, the levels of EC-SOD and tetranectin significantly decreased. Conclusion: Our preliminary results suggest that variations in the expression levels of EC-SOD and tetranectin in CSF is related to DBS.

show abstract

Section: Discussionsupporting

confidence: 80%

Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation

Wang

Yao

Chen

et al. 2013

Cell Physiol Biochem

858

View full text Add to dashboard Cite

show abstract

“…The biological function of TN has not been fully elucidated, though it is thought to play an important role in the regulation of proteolytic and fibrinolysis processes by binding to plasminogen. It is also believed to play a critical role in mineralization during osteogenesis and in myogenesis during embryonic development [19]. Furthermore, TN has been implicated as a potential biomarker in conditions ranging from cancer to Parkinson's disease [20].…”

Section: Discussionmentioning

confidence: 99%

Proteomics study of serum exosomes in Kawasaki disease patients with coronary artery aneurysms

Xie

Chu

et al. 2019

Cardiol J.

View full text Add to dashboard Cite

show abstract

“…ApoA1 together with another apolipoprotein, apoE are responsible for lipid transportation in the brain. Lower levels of one isoform of apoA1 and tetranectin are reported in the CSF of PD patients, suggesting that apoA1 is a potential biomarker for PD (Wang et al, 2010; Swanson et al, 2015). ApoA1 cannot be secreted from neurons, but as the main component of HDL, it is required for cholesterol transportation to the brain.…”

Section: Neurochemical Biomarkersmentioning

confidence: 99%

Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors

2018

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused mainly by lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement, motivation, memory, and other functions; its level is decreased in PD brain as a result of dopaminergic cell death. Dopamine loss in PD brain is a cause of motor deficiency and, possibly, a reason of the cognitive deficit observed in some PD patients. PD is mostly not recognized in its early stage because of a long latency between the first damage to dopaminergic cells and the onset of clinical symptoms. Therefore, it is very important to find reliable molecular biomarkers that can distinguish PD from other conditions, monitor its progression, or give an indication of a positive response to a therapeutic intervention. PD biomarkers can be subdivided into four main types: clinical, imaging, biochemical, and genetic. For a long time protein biomarkers, dopamine metabolites, amino acids, etc. in blood, serum, cerebrospinal liquid (CSF) were considered the most promising. Among the candidate biomarkers that have been tested, various forms of α-synuclein (α-syn), i.e., soluble, aggregated, post-translationally modified, etc. were considered potentially the most efficient. However, the encouraging recent results suggest that microRNA-based analysis may bring considerable progress, especially if it is combined with α-syn data. Another promising analysis is the advanced metabolite profiling of body fluids, called “metabolomics” which may uncover metabolic fingerprints specific for various stages of PD. Conventional pharmacological treatment of PD is based on the replacement of dopamine using dopamine precursors (levodopa, L-DOPA, L-3,4 dihydroxyphenylalanine), dopamine agonists (amantadine, apomorphine) and MAO-B inhibitors (selegiline, rasagiline), which can be used alone or in combination with each other. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects. This review covers molecules that might act as the biomarkers of PD. Then, PD risk factors (including genetics and non-genetic factors) and PD treatment options are discussed.

show abstract

Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease

Abstract: Our preliminary results suggest that tetranectin and apoA-I may serve as potential biomarkers for PD, though further validation is needed.

Cited by 39 publications

References 46 publications

Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation

Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation

Proteomics study of serum exosomes in Kawasaki disease patients with coronary artery aneurysms

Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors

Contact Info

Product

Resources

About